Pressmeddelanden från Navamedic

Bevaka pressreleaser

Start Nyheter Pressreleaser Riktkurser Insynshandel Blankning Analyser Bloggar Videos Podcasts

Navamedic ASA: Steady performance and continued product launch in Q1 2026 12 feb 07:00

Navamedic ASA: Strong growth and important product launch in Q4 2025 28 okt 2025 07:00

Navamedic ASA: Double digit growth in the 3rd quarter, 2025 24 okt 2025 17:56

Navamedic ASA: Invitation to 2025 3rd quarter presentation 13 okt 2025 18:25

Navamedic ASA – New share capital registered 07 okt 2025 12:55

Navamedic ASA: Allocation of shares in the rights issue to primary insiders and their close associates 07 okt 2025 12:42

Navamedic ASA: Final results of the rights issue 06 okt 2025 20:47

Navamedic ASA: Preliminary results of the rights issue 06 okt 2025 08:00

Navamedic ASA: Last day of the subscription period in the rights issue 03 okt 2025 19:49

Navamedic ASA: Mandatory notification of trades by primary insiders and their close associates 30 sep 2025 08:00

Navamedic ASA: Last day of trading in subscription rights 22 sep 2025 21:26

Navamedic ASA: Receipt of subscription rights in the rights issue by primary insiders and their close associates 22 sep 2025 07:30

Navamedic ASA: Commencement of the subscription period for the rights issue 19 sep 2025 11:05

Navamedic ASA: Approval and publication of prospectus 01 sep 2025 12:45

Navamedic ASA: Updated key information relating to the rights issue 14 aug 2025 07:00

Navamedic ASA: Financial report for the 2nd quarter and first half of 2025 11 aug 2025 13:03

Navamedic ASA: Invitation to 2025 2nd quarter presentation 15 jul 2025 12:32

Navamedic ASA: Closing of the transaction to acquire the business of dne pharma 14 jul 2025 15:27

Navamedic ASA - Minutes of Extraordinary General Meeting 29 jun 2025 13:36

Navamedic ASA – Additional underwriting commitments in the Rights Issue 27 jun 2025 14:14

Navamedic ASA: First approval of the medical device OraFID® as primary package for a pharmaceutical product 24 jun 2025 08:00

Navamedic ASA – Investor presentation regarding the acquisition of the business of dne pharma AS 23 jun 2025 12:45

Navamedic ASA: Notice of extraordinary general meeting on 14 July 2025 in connection with a contemplated rights issue 23 jun 2025 08:15

Navamedic ASA: Key information relating to the Rights Issue 23 jun 2025 08:00

Navamedic ASA expands into addiction treatment through the acquisition of the business of dne pharma and announces a partially underwritten rights issue 04 jun 2025 10:29

Navamedic ASA: Minutes of Annual General Meeting 14 maj 2025 14:35

Navamedic ASA: Notice of Annual General Meeting 30 apr 2025 19:42

Navamedic ASA: Annual Report 2024 30 apr 2025 07:00

Navamedic Q1 2025: Strong start of the year and well-positioned for future growth 29 apr 2025 17:35

Navamedic ASA: Imdur® distribution agreement extended to 2032 28 apr 2025 12:06

Navamedic ASA: Invitation to 2025 1st quarter presentation 12 feb 2025 07:00

Navamedic Q4 and Full Year 2024: Continued growth in a year with investments in new growth initiatives 10 feb 2025 11:00

Navamedic ASA: Invitation to 2024 4th quarter presentation 15 nov 2024 13:00

Navamedic ASA: Amendments to loan agreements with Observe Medical ASA 06 nov 2024 13:52

Navamedic ASA: Mandatory notice of trade 06 nov 2024 09:10

Navamedic launches Eroxon[®] in Finland 31 okt 2024 07:00

Navamedic Q3 2024: Business remains strong in quarter impacted by cyclical nature of the business 28 okt 2024 09:08

Navamedic ASA: Invitation to 2024 3rd quarter presentation 07 okt 2024 13:56

Navamedic wins joint Nordic antibiotics tender 12 sep 2024 12:00

Navamedic announces an exclusive agreement with Alex Therapeutics for the development of a Companion App to aid in the treatment of Parkinson’s Disease 09 sep 2024 16:47

Navamedic ASA – Mandatory notification of trade by primary insider 09 sep 2024 16:03

NAVAMEDIC ASA: RESOLUTION TO INCREASE THE SHARE CAPITAL IN CONNECTION WITH EXERCISE OF EMPLOYEE OPTIONS 16 aug 2024 07:00

Navamedic Q2 and H1 2024: Stable growth continues and is supported by a new licensing and supply agreement 12 aug 2024 10:00

Navamedic ASA: Invitation to 2024 2nd quarter presentation 24 jun 2024 16:19

Navamedic and Orion Corporation sign License & Supply Agreement for Flexilev® in Europe 04 jun 2024 10:18

Navamedic ASA: Minutes of Annual General Meeting 16 maj 2024 09:00

Navamedic ASA: Renewed contract for delivering antibiotics to Norwegian hospitals 14 maj 2024 14:10

Navamedic ASA: Notice of Annual General Meeting 06 maj 2024 11:00

Första behandlingen mot erektionsproblem utan recept lanseras på svenska apotek 06 maj 2024 11:00

Navamedic ASA: Broad launch for Eroxon® in Sweden today 30 apr 2024 17:45

Navamedic ASA: Annual Report 2023 30 apr 2024 07:00

Navamedic Q1 2024: Successful product launch and steady operational progress 23 apr 2024 14:30

Navamedic ASA: Invitation to 2024 1st quarter presentation 02 apr 2024 14:38

Navamedic ASA – Registration of share capital increase 13 mar 2024 10:31

Navamedic welcomes new shareholders 15 feb 2024 08:00

Navamedic Q4 and full year 2023: A year marked by new records and transformative growth initiatives 13 feb 2024 08:00

Navamedic ASA: Invitation to 2023 4th quarter presentation 21 dec 2023 17:20

Navamedic ASA: Renewed contract signed with Vitaflo International Limited 13 dec 2023 18:51

Navamedic and Orion Corporation sign non-binding term sheet for Flexilev® in Europe 01 nov 2023 08:00

Navamedic ASA: Record high quarter with above 50 percent growth 27 okt 2023 11:13

Navamedic ASA: Invitation to 2023 3rd quarter presentation 18 aug 2023 12:31

Navamedic ASA – Mandatory notification of trade by primary insider 18 aug 2023 11:56

NAVAMEDIC ASA: Resolution to increase the share capital in connection with exercise of employee options 11 aug 2023 08:00

Navamedic ASA: Significant growth across the business 07 aug 2023 12:24

Navamedic ASA: Invitation to 2023 2nd quarter presentation 01 jun 2023 11:35

Navamedic ASA: Minutes of Annual General Meeting 31 maj 2023 14:16

Updated recommendation by the nomination committee of Navamedic ASA 26 maj 2023 08:00

Navamedic to own a total of 96.33 per cent of shares in Sensidose following closing of public offer 26 maj 2023 08:00

Navamedic offentliggör slutligt utfall i erbjudandet till aktieägarna och innehavarna av teckningsoptioner av serie TO 1 i Sensidose Aktiebolag 26 maj 2023 08:00

Navamedic announces the final outcome in the offer to the shareholders and holders of warrants of series TO 1 in Sensidose Aktiebolag 17 maj 2023 17:45

Navamedic publishes a supplement to the offer document regarding the unconditional cash offer to the shareholders and holders of warrants of series TO 1 in Sensidose Aktiebolag 17 maj 2023 17:45

Navamedic offentliggör ett tillägg till erbjudandehandlingen avseende det ovillkorade kontanterbjudandet till aktieägare och innehavare av teckningsoptioner av serie TO 1 i Sensidose Aktiebolag 12 maj 2023 15:00

Navamedic publishes a supplement to the offer document regarding the unconditional cash offer to the shareholders and holders of warrants of series TO 1 in Sensidose Aktiebolag 12 maj 2023 15:00

Navamedic offentliggör ett tillägg till erbjudandehandlingen avseende det ovillkorade kontanterbjudandet till aktieägare och innehavare av teckningsoptioner av serie TO 1 i Sensidose Aktiebolag 11 maj 2023 12:00

Navamedic ASA: Notice of Annual General Meeting 11 maj 2023 08:00

Navamedic ASA Q1 2023: Another strong quarter 10 maj 2023 09:00

Navamedic höjer vederlaget till 8,50 kronor kontant per aktie i sitt ovillkorade offentliga uppköpserbjudande och kallar till extra bolagsstämma i Sensidose Aktiebolag 10 maj 2023 09:00

Navamedic increases the consideration to SEK 8.50 in cash per share in its unconditional public offer and convenes an extraordinary general meeting of Sensidose Aktiebolag 08 maj 2023 10:41

Navamedic ASA: Invitation to 2023 1st quarter presentation 28 apr 2023 15:10

Navamedic offentliggör ett tillägg till erbjudandehandlingen avseende det ovillkorade kontanterbjudandet till aktieägare och innehavare av teckningsoptioner av serie TO 1 i Sensidose Aktiebolag 28 apr 2023 15:10

Navamedic publishes a supplement to the offer document regarding the unconditional cash offer to the shareholders and holders of warrants of series TO 1 in Sensidose Aktiebolag 28 apr 2023 13:20

Navamedic ASA: Annual Report for 2022 26 apr 2023 12:20

Navamedic increases the consideration to SEK 0.60 in cash per warrant of series TO 1 in its unconditional offer to the warrant holders in Sensidose Aktiebolag 26 apr 2023 12:20

Navamedic höjer vederlaget till 0,60 kronor kontant per teckningsoption av serie TO 1 i det ovillkorade erbjudandet till teckningsoptionsinnehavarna i Sensidose Aktiebolag 25 apr 2023 22:10

Navamedic ASA utökar sitt erbjudande till att omfatta teckningsoptioner av serie TO 1 emitterade av Sensidose Aktiebolag till ett pris om 0,38 kronor kontant per teckningsoption av serie TO 1 25 apr 2023 22:10

Navamedic ASA expands its offer to include warrants of series TO 1 issued by Sensidose Aktiebolag at a price of SEK 0.38 in cash per warrant of series TO 1 24 apr 2023 22:45

Correction: Navamedic publishes a supplement to the offer document regarding the cash offer to the shareholders of Sensidose Aktiebolag 24 apr 2023 21:30

Navamedic offentliggör ett tillägg till erbjudandehandlingen avseende dess kontanterbjudande till aktieägarna i Sensidose Aktiebolag 24 apr 2023 21:30

Navamedic publishes a supplement to the offer document regarding the recommended cash offer to the shareholders of Sensidose Aktiebolag 22 apr 2023 13:10

Navamedic ASA: Amended cash offer to acquire Sensidose AB and acquisition of shares in Sensidose AB 22 apr 2023 13:00

Navamedic completes the offer, has entered into agreements to acquire approximately 56.7 per cent of the shares in Sensidose and increases the consideration to SEK 8 in cash per share 22 apr 2023 13:00

Navamedic fullföljer erbjudandet, har ingått avtal om förvärv av cirka 56,7 procent av aktierna i Sensidose och höjer vederlaget till 8 kronor kontant per aktie i Sensidose 29 mar 2023 07:30

Navamedic ASA announces a unanimously recommended cash offer of SEK 6.27 per share to the shareholders of Sensidose Aktiebolag 29 mar 2023 07:30

Navamedic ASA lämnar ett enhälligt rekommenderat kontanterbjudande om 6,27 kronor per aktie till aktieägarna i Sensidose Aktiebolag 16 feb 2023 08:00

Navamedic ASA: Q4 2022 financial results 13 feb 2023 09:00

Navamedic ASA: Invitation to 2022 4th quarter presentation 23 nov 2022 10:05

Navamedic ASA acquires innovative antibiotic product for hospital use in the Nordic region 01 nov 2022 08:00

Navamedic ASA: Q3 2022 financial results 25 okt 2022 15:41

Navamedic ASA: Invitation to 2022 third quarter presentation 20 okt 2022 08:40

Navamedic ASA launches ForlaxGO® - an innovative on-the-go product for the treatment of constipation